Search results for "DASE"

showing 10 items of 1891 documents

A new PCSK9 gene promoter variant affects gene expression and causes autosomal dominant hypercholesterolemia.

2008

Autosomal dominant hypercholesterolemia (ADH) is a genetic disorder characterized by increased low-density lipoprotein (LDL)-cholesterol levels, leading to high risk of premature cardiovascular disease. More than 900 mutations in LDL receptor, six in APOB and 10 in PCSK9 have been identified as a cause of the disease in different populations. All known mutations in PCSK9 causing hypercholesterolemia produce an increase in the enzymatic activity of this protease. Up to now, there are data about the implication of PCSK9 in ADH in a low number of populations, not including a Spanish population.The objective of the study was to study the prevalence of PCSK9 mutations in ADH Spanish population.W…

Adultmedicine.medical_specialtyApolipoprotein BEndocrinology Diabetes and MetabolismClinical BiochemistryGene ExpressionTransfectionBiochemistryPolymorphism Single NucleotideHyperlipoproteinemia Type IIPCSK9 GeneMiceEndocrinologyGene FrequencyInternal medicinemedicineAnimalsHumansPromoter Regions GeneticAllele frequencyGeneCells CulturedGeneticsbiologyBase SequencePCSK9Biochemistry (medical)Serine EndopeptidasesGenetic disorderHyperlipoproteinemia Type IIaMiddle Agedmedicine.diseaseEndocrinologySpainCase-Control StudiesLDL receptorbiology.proteinNIH 3T3 Cellslipids (amino acids peptides and proteins)Mutant ProteinsProprotein ConvertasesProprotein Convertase 9The Journal of clinical endocrinology and metabolism
researchProduct

Iodine deficiency during pregnancy: a national cross-sectional survey in Latvia

2015

AbstractObjectiveLow iodine intake during pregnancy may cause thyroid dysfunction, which results in inadequate fetal brain development. In the absence of a universal salt iodization programme, we conducted a nationwide survey of iodine deficiency in pregnant women in Latvia.DesignA countrywide twenty-cluster survey, with at least twenty women per cluster. Participants completed a questionnaire on dietary habits concerning iodine intake (n 739). Thyroid function (thyroid-stimulating hormone, free thyroxine and thyroperoxidase antibodies) was measured (n 550). Urinary iodine was measured using the ammonium persulfate method (n 696).SettingThe survey was performed in all regions of Latvia duri…

Adultmedicine.medical_specialtyCross-sectional studyThyroid GlandNutritional StatusMedicine (miscellaneous)chemistry.chemical_elementIodineDiet Surveyschemistry.chemical_compoundPregnancyThyroid peroxidaseInterquartile rangemedicineHumansSodium Chloride DietaryGynecologyPregnancyCreatinineNutrition and Dieteticsbiologybusiness.industryPublic Health Environmental and Occupational HealthFeeding Behaviormedicine.diseaseResearch PapersLatviaIodine deficiencyDietPregnancy ComplicationsCross-Sectional StudieschemistryDietary Supplementsbiology.proteinFemalePregnancy TrimestersThyroid functionDeficiency DiseasesbusinessIodinePublic Health Nutrition
researchProduct

Association between exposure to organochlorine compounds and maternal thyroid status: Role of the iodothyronine deiodinase 1 gene.

2017

Introduction: Exposure to organochlorine compounds (OCs) may interfere with thyroid hormone (TH) homeostasis. The disruption of the deiodinase (DIO) enzymes has been proposed as a mechanism of action. Aim: To evaluate the association between exposure to OCs and TH status in pregnant women, as well as to explore the role of genetic variations in the DIO1 and DIO2 genes. Methods: The study population (n = 1128) was composed of pregnant women who participated in the INMA Project (Spain, 2003–2006). Hexachlorobenzene (HCB), 1,1-dichloro-2,2-bis(4-chlorophenyl)ethylene (4,4´-DDE), b-hexachlorocyclohexane (b-HCH), polychlorobiphenyl (PCB) congeners 138, 153 and 180, thyroid stimulating hormone (T…

Adultmedicine.medical_specialtyDeiodinaseDIO2Thyrotropin010501 environmental sciences01 natural sciencesIodide Peroxidase03 medical and health sciences0302 clinical medicineThyroid-stimulating hormonePregnancyInternal medicinemedicineHydrocarbons ChlorinatedHumans030212 general & internal medicineDeiodinase enzymeslcsh:Environmental sciences0105 earth and related environmental sciencesGeneral Environmental Sciencelcsh:GE1-350ThyroidPregnancyTriiodothyroninebiologyChemistryThyroidOrganochlorine compoundsFetal developmentmedicine.diseaseDietPregnancy Trimester FirstThyroxinemedicine.anatomical_structureEndocrinologySpainbiology.proteinGestationTriiodothyronineFemaleHormoneEnvironment international
researchProduct

CARDIAC PUNCTURE OF FETUS WITH HURLER'S DISEASE AVOIDING ABORTION OF UNAFFECTED CO-TWIN

1978

Adultmedicine.medical_specialtyFetal ResorptionMucopolysaccharidosis IFetal heartPuncturesDiseaseAbortionIduronidaseFetal HeartPregnancyPrenatal DiagnosisDiseases in TwinsHumansMedicineFetal DeathGlucuronidaseGlycosaminoglycansFetusPregnancyFetal deathbusiness.industryObstetricsInfant NewbornFollow up studiesInfantFetal ResorptionGeneral MedicineFibroblastsAmniotic Fluidbeta-Galactosidasemedicine.diseaseAnesthesiaFemalebusinessFollow-Up StudiesThe Lancet
researchProduct

Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study.

2003

Summary: Fabry disease is an X-linked glycosphingolipid storage disorder caused by a deficiency of α-galactosidase A. Affected patients experience debilitating neuropathic pain and have premature mortality due to renal failure, cardiovascular disease or cerebrovascular complications. The disease may be X-linked dominant, since most females heterozygous for Fabry disease are affected clinically. We evaluated the safety, efficacy and pharmacokinetics of agalsidase alfa (Replagal) administered intravenously to female patients with Fabry disease in an open-label, single-centre study. Fifteen severely affected patients received agalsidase alfa at 0.2 mg/kg every other week for up to 55 weeks. Ag…

Adultmedicine.medical_specialtyHeterozygoteAdolescentArthritisRenal functionKidneyGastroenterologyAntibodiesArthritis RheumatoidElectrocardiographyPharmacokineticsInternal medicineGeneticsmedicineHumansGenetics (clinical)Vascular diseasebusiness.industryTrihexosylceramidesEnzyme replacement therapymedicine.diseaseFabry diseaseRecombinant ProteinsSurgeryClinical trialIsoenzymesEchocardiographyalpha-GalactosidaseNeuropathic painMutationFabry DiseaseFemalebusinessJournal of inherited metabolic disease
researchProduct

Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy.

2013

Abstract Objective To determine the spectrum of gene mutations and the genotype–phenotype correlations in patients with Autosomal Dominant Hypercholesterolemia (ADH) identified in Italy. Methods The resequencing of LDLR , PCSK9 genes and a selected region of APOB gene were conducted in 1018 index subjects clinically heterozygous ADH and in 52 patients clinically homozygous ADH. The analysis was also extended to 1008 family members of mutation positive subjects. Results Mutations were detected in 832 individuals: 97.4% with LDLR mutations, 2.2% with APOB mutations and 0.36% with PCSK9 mutations. Among the patients with homozygous ADH, 51 were carriers of LDLR mutations and one was an LDLR / …

Adultmedicine.medical_specialtyHeterozygoteSettore MED/09 - Medicina InternaApolipoprotein BCoronary DiseaseBiologyGene mutationmedicine.disease_causeHyperlipoproteinemia Type IITendonschemistry.chemical_compoundReference ValuesInternal medicinemedicineXanthomatosisHumansGeneAllelesGenetic Association StudiesAgedGeneticsMutationCholesterolPCSK9Cholesterol HDLSerine EndopeptidasesSmokingAlcohol Dehydrogenasenutritional and metabolic diseasesCholesterol LDLMiddle AgedEndocrinologyPhenotypechemistryItalyLDL receptorMutationbiology.proteinAutosomal dominanthypercholesterolemia LDL receptor Apolipoprotein B PCSK9 Mutationslipids (amino acids peptides and proteins)Allelic heterogeneityFemaleProprotein ConvertasesProprotein Convertase 9Cardiology and Cardiovascular MedicineAtherosclerosis
researchProduct

The Influence of Oxidative Stress on Neurological Outcomes in Spontaneous Intracerebral Hemorrhage

2021

Spontaneous intracerebral hemorrhage (ICH) causes, besides the primary brain injury, a secondary brain injury (SBI), which is induced, amongst other things, by oxidative stress (OS) and inflammation, determining the patient’s outcome. This study aims to assess the impact of OS in plasma and cerebrospinal fluid (CSF) on clinical outcomes in patients with ICH. A total of 19 ICH (volume &gt

Adultmedicine.medical_specialtyInflammationmedicine.disease_causeBiochemistryGastroenterologyMicrobiologyArticlecerebrospinal fluidSuperoxide dismutasechemistry.chemical_compoundCerebrospinal fluidInternal medicineMalondialdehydemedicineHumansoxidative stresscardiovascular diseasesMolecular Biologyneurological outcomeCerebral Hemorrhagechemistry.chemical_classificationIntracerebral hemorrhageGlutathione Peroxidasebiologybusiness.industryGlutathione peroxidaseGlutathioneMiddle AgedMalondialdehydemedicine.diseaseintracerebral hemorrhageQR1-502nervous system diseaseschemistrybiology.proteinmedicine.symptombusinessOxidative stressoxidative stress markersBiomolecules
researchProduct

Oxidant mechanisms in childhood obesity: the link between inflammation and oxidative stress.

2011

Evidence of obesity-induced oxidative stress in adults has emerged in the past several years, and similar evidence has been demonstrated in children more recently. The reactive species of oxygen or nitrogen can chemically alter all major classes of biomolecules by modifying their structure and function. Organisms have developed mechanisms to protect biomolecules from the deleterious effects of free radicals. These include the enzymes superoxide dismutase, catalase, and glutathione peroxidase, as well as water and lipid-soluble antioxidants, such as glutathione, ascorbate (vitamin C), α-tocopherol (vitamin E), and β-carotene. Obesity creates oxidant conditions that favor the development of c…

Adultmedicine.medical_specialtyOxidative phosphorylationSystemic inflammationmedicine.disease_causeSuperoxide dismutasechemistry.chemical_compoundRisk FactorsPhysiology (medical)Internal medicinemedicineHumansObesityChildchemistry.chemical_classificationInflammationReactive oxygen speciesbiologybusiness.industryGlutathione peroxidaseBiochemistry (medical)Public Health Environmental and Occupational HealthGeneral MedicineGlutathioneMalondialdehydeOxidantsOxidative StressEndocrinologychemistrybiology.proteinmedicine.symptomMorbiditybusinessOxidative stressTranslational research : the journal of laboratory and clinical medicine
researchProduct

A 4-year study of the efficacy and tolerability of enzyme replacement therapy with agalsidase alfa in 36 women with Fabry disease

2009

Although Fabry disease is X linked and considered to affect primarily male hemizygotes, female heterozygotes may experience all the signs and symptoms of this metabolic disorder. This prospective, single-center, open-label, clinical trial was performed to evaluate the long-term response of female patients with Fabry disease to enzyme replacement therapy.Symptomatic women (average age = 47 years) enrolled in this 4-year study were treated with agalsidase alfa (Replagal, Shire HGT, Inc.) at a dose of 0.2 mg/kg, every other week for 4 years (N = 36). Clinical and biochemical assessments were conducted at 12-month intervals.The Mainz Severity Score Index, a measure of total disease burden, was …

Adultmedicine.medical_specialtyTreatment outcomeSeverity of Illness IndexDrug Administration ScheduleYoung Adultstomatognathic systemInternal medicineSeverity of illnessLeukocytesmedicineHumansProspective StudiesProspective cohort studyGenetics (clinical)AgedAnalysis of Variancebusiness.industryvirus diseasesEnzyme replacement therapyMiddle Agedmedicine.diseaseFabry diseaseRecombinant Proteinsdigestive system diseasesIsoenzymesClinical trialTreatment OutcomeTolerabilityalpha-GalactosidaseMutationPhysical therapyFabry DiseaseFemalebusinessAgalsidase alfaGlomerular Filtration RateGenetics in Medicine
researchProduct

Aging Negatively Affects Estrogens-Mediated Effects on Nitric Oxide Bioavailability by Shifting ERα/ERβ Balance in Female Mice

2011

AIMS: Aging is among the major causes for the lack of cardiovascular protection by estrogen (E2) during postmenopause. Our study aims to determine the mechanisms whereby aging changes E2 effects on nitric oxide (NO) production in a mouse model of accelerated senescence (SAM). METHODS AND RESULTS: Although we found no differences on NO production in females SAM prone (SAMP, aged) compared to SAM resistant (SAMR, young), by either DAF-2 fluorescence or plasmatic nitrite/nitrate (NO2/NO3), in both cases, E2 treatment increased NO production in SAMR but had no effect in SAMP. Those results are in agreement with changes of eNOS protein and gene expression. E2 up-regulated eNOS expression in SAMR…

AgingAnatomy and Physiologylcsh:MedicineEstrogen receptorFluorescent Antibody TechniqueCardiovascularCardiovascular SystemBiochemistrychemistry.chemical_compoundMiceEndocrinologyEnosMolecular Cell BiologyMembrane Receptor Signalinglcsh:ScienceReceptorMultidisciplinarybiologySuperoxideNeurochemistryHormone Receptor SignalingReceptors EstrogenDNA methylationCirculatory PhysiologyMedicineFemaleNeurochemicalsResearch ArticleSignal TransductionSenescencemedicine.medical_specialtymedicine.drug_classBlotting WesternEndocrine SystemNitric OxideReal-Time Polymerase Chain ReactionCardiovascular PharmacologyNitric oxideInternal medicinemedicineCardiovascular Diseases in WomenAnimalsBiologyEndocrine Physiologylcsh:RNADPH OxidasesEstrogensDNA Methylationbiology.organism_classificationHormonesEndocrinologychemistryEstrogenWomen's Healthlcsh:QNeurosciencePLoS ONE
researchProduct